Standing Order
All companies

Biotech

Alnylam Pharmaceuticals, Inc.

ALNYNASDAQpure-play
Market cap$19B
Conviction5/ 5
HQCambridge, MA
View full dashboard

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Price · 1Y

$143.82

-53.0%

Thesis

Alnylam is the RNA-interference (RNAi) platform leader, having turned a Nobel-winning mechanism into a commercial franchise of approved silencing therapeutics. AMVUTTRA's expansion into ATTR cardiomyopathy moves the company from rare-disease revenue into a large cardiovascular market, the inflection that underwrites sustained profitability.

The investment case is a durable, reusable platform — one delivery-and-chemistry stack applied across many indications — now reaching commercial scale and self-funding its pipeline. Risks: competition in the TTR market (Pfizer's tafamidis, BridgeBio, Ionis), pricing pressure, and the usual clinical risk on next-wave cardiometabolic programs.

Catalysts

  • AMVUTTRA ATTR-cardiomyopathy launch trajectory
  • TTR-market competitive dynamics
  • Cardiometabolic pipeline readouts (e.g. subcutaneous programs)
  • Margin inflection as the commercial base scales

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

  • Nov 5
    LeadershipSEC

    8-K filed with items 5.02 and 8.01 on 2026-11-05 regarding director or officer matters.

  • Oct 29
    Financial resultsSEC

    Alnylam filed 8-K (items 2.02, 9.01) reporting financial results.

  • Jul 30
    Financial resultsSEC

    Filed 8-K (items 2.02, 9.01) disclosing results of operations and financial condition.

Not financial advice — research and opinion only. Disclosures